CN101313978B - Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof - Google Patents
Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof Download PDFInfo
- Publication number
- CN101313978B CN101313978B CN2008100290615A CN200810029061A CN101313978B CN 101313978 B CN101313978 B CN 101313978B CN 2008100290615 A CN2008100290615 A CN 2008100290615A CN 200810029061 A CN200810029061 A CN 200810029061A CN 101313978 B CN101313978 B CN 101313978B
- Authority
- CN
- China
- Prior art keywords
- portions
- parts
- oral liquid
- synergistic agent
- liquid synergistic
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 31
- 239000012747 synergistic agent Substances 0.000 title claims abstract description 27
- 229960005486 vaccine Drugs 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 9
- 241000588724 Escherichia coli Species 0.000 title claims description 15
- 244000144977 poultry Species 0.000 title claims description 7
- 238000004519 manufacturing process Methods 0.000 title description 2
- 244000144972 livestock Species 0.000 title 1
- 239000002994 raw material Substances 0.000 claims abstract description 11
- OJMMVQQUTAEWLP-UHFFFAOYSA-N Lincomycin Natural products CN1CC(CCC)CC1C(=O)NC(C(C)O)C1C(O)C(O)C(O)C(SC)O1 OJMMVQQUTAEWLP-UHFFFAOYSA-N 0.000 claims abstract description 9
- 241001116389 Aloe Species 0.000 claims abstract description 8
- 235000011399 aloe vera Nutrition 0.000 claims abstract description 8
- 235000021551 crystal sugar Nutrition 0.000 claims abstract description 8
- OJMMVQQUTAEWLP-KIDUDLJLSA-N lincomycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@@H](C)O)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 OJMMVQQUTAEWLP-KIDUDLJLSA-N 0.000 claims abstract description 7
- 229960005287 lincomycin Drugs 0.000 claims abstract description 7
- UNFWWIHTNXNPBV-WXKVUWSESA-N spectinomycin Chemical compound O([C@@H]1[C@@H](NC)[C@@H](O)[C@H]([C@@H]([C@H]1O1)O)NC)[C@]2(O)[C@H]1O[C@H](C)CC2=O UNFWWIHTNXNPBV-WXKVUWSESA-N 0.000 claims abstract description 7
- 229960000268 spectinomycin Drugs 0.000 claims abstract description 7
- 239000003814 drug Substances 0.000 claims abstract 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 32
- 241001465754 Metazoa Species 0.000 claims description 13
- 229960000583 acetic acid Drugs 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000284 extract Substances 0.000 claims description 8
- 241000746375 Andrographis Species 0.000 claims description 7
- 238000003756 stirring Methods 0.000 claims description 6
- 239000009806 pulsatillae Substances 0.000 claims description 5
- 239000000706 filtrate Substances 0.000 claims description 4
- 239000012467 final product Substances 0.000 claims description 4
- 239000012362 glacial acetic acid Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 238000005303 weighing Methods 0.000 claims description 4
- 235000016993 Agrimonia Nutrition 0.000 claims description 2
- 241000206469 Pulsatilla Species 0.000 claims description 2
- 239000012141 concentrate Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 241001092084 Agrimonia Species 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 8
- 239000008280 blood Substances 0.000 abstract description 4
- 210000004369 blood Anatomy 0.000 abstract description 4
- 239000003053 toxin Substances 0.000 abstract description 4
- 231100000765 toxin Toxicity 0.000 abstract description 4
- 238000000034 method Methods 0.000 abstract description 3
- 241000193830 Bacillus <bacterium> Species 0.000 abstract 2
- 210000001072 colon Anatomy 0.000 abstract 2
- 231100000331 toxic Toxicity 0.000 abstract 2
- 230000002588 toxic effect Effects 0.000 abstract 2
- 244000118350 Andrographis paniculata Species 0.000 abstract 1
- 241000675108 Citrus tangerina Species 0.000 abstract 1
- 241001673966 Magnolia officinalis Species 0.000 abstract 1
- 241001504477 Pycnonotidae Species 0.000 abstract 1
- 235000014220 Rhus chinensis Nutrition 0.000 abstract 1
- 240000003152 Rhus chinensis Species 0.000 abstract 1
- 241000270295 Serpentes Species 0.000 abstract 1
- 230000035622 drinking Effects 0.000 abstract 1
- 208000028774 intestinal disease Diseases 0.000 abstract 1
- 239000000463 material Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 208000011580 syndromic disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 17
- 201000010099 disease Diseases 0.000 description 14
- 208000015181 infectious disease Diseases 0.000 description 11
- 241000287828 Gallus gallus Species 0.000 description 10
- 241000282898 Sus scrofa Species 0.000 description 10
- 235000013330 chicken meat Nutrition 0.000 description 10
- 230000002265 prevention Effects 0.000 description 6
- 208000035473 Communicable disease Diseases 0.000 description 5
- 230000036039 immunity Effects 0.000 description 5
- 231100000614 poison Toxicity 0.000 description 5
- 235000013594 poultry meat Nutrition 0.000 description 5
- 208000037920 primary disease Diseases 0.000 description 5
- 230000003203 everyday effect Effects 0.000 description 4
- 206010025482 malaise Diseases 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000003440 toxic substance Substances 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 3
- 238000009395 breeding Methods 0.000 description 3
- 230000001488 breeding effect Effects 0.000 description 3
- 230000001717 pathogenic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 241000272517 Anseriformes Species 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000840 anti-viral effect Effects 0.000 description 2
- 208000001848 dysentery Diseases 0.000 description 2
- 208000029182 enterotoxemia Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000012447 hatching Effects 0.000 description 2
- 210000002429 large intestine Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000003405 preventing effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- 238000010926 purge Methods 0.000 description 2
- 210000000952 spleen Anatomy 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 244000307697 Agrimonia eupatoria Species 0.000 description 1
- 241000272525 Anas platyrhynchos Species 0.000 description 1
- 208000031504 Asymptomatic Infections Diseases 0.000 description 1
- 208000027312 Bursal disease Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000035240 Disease Resistance Diseases 0.000 description 1
- 102000002322 Egg Proteins Human genes 0.000 description 1
- 108010000912 Egg Proteins Proteins 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000025309 Hair disease Diseases 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 239000004100 Oxytetracycline Substances 0.000 description 1
- 206010039438 Salmonella Infections Diseases 0.000 description 1
- 206010040943 Skin Ulcer Diseases 0.000 description 1
- 241000193395 Sporosarcina pasteurii Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 230000002180 anti-stress Effects 0.000 description 1
- 230000002155 anti-virotic effect Effects 0.000 description 1
- 238000009360 aquaculture Methods 0.000 description 1
- 244000144974 aquaculture Species 0.000 description 1
- 239000003212 astringent agent Substances 0.000 description 1
- 244000052616 bacterial pathogen Species 0.000 description 1
- 210000000941 bile Anatomy 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 206010006451 bronchitis Diseases 0.000 description 1
- 244000144987 brood Species 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 230000002354 daily effect Effects 0.000 description 1
- 230000000994 depressogenic effect Effects 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 238000009792 diffusion process Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 208000034653 disorder of pilosebaceous unit Diseases 0.000 description 1
- 239000003651 drinking water Substances 0.000 description 1
- 235000020188 drinking water Nutrition 0.000 description 1
- 238000001647 drug administration Methods 0.000 description 1
- 239000003640 drug residue Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 230000003419 expectorant effect Effects 0.000 description 1
- 230000004438 eyesight Effects 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 239000007952 growth promoter Substances 0.000 description 1
- 230000005571 horizontal transmission Effects 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 210000000867 larynx Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000004792 malaria Diseases 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 210000004681 ovum Anatomy 0.000 description 1
- IWVCMVBTMGNXQD-PXOLEDIWSA-N oxytetracycline Chemical compound C1=CC=C2[C@](O)(C)[C@H]3[C@H](O)[C@H]4[C@H](N(C)C)C(O)=C(C(N)=O)C(=O)[C@@]4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-PXOLEDIWSA-N 0.000 description 1
- 229960000625 oxytetracycline Drugs 0.000 description 1
- 235000019366 oxytetracycline Nutrition 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 206010039447 salmonellosis Diseases 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- IWVCMVBTMGNXQD-UHFFFAOYSA-N terramycin dehydrate Natural products C1=CC=C2C(O)(C)C3C(O)C4C(N(C)C)C(O)=C(C(N)=O)C(=O)C4(O)C(O)=C3C(=O)C2=C1O IWVCMVBTMGNXQD-UHFFFAOYSA-N 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000008733 trauma Effects 0.000 description 1
- 210000003954 umbilical cord Anatomy 0.000 description 1
- 230000005570 vertical transmission Effects 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Abstract
The invention relates to a veterinary medicine composition and a preparation method thereof. A colon bacillus vaccine oral liquid synergistic agent is mainly prepared by the following raw materials by weight portion: 5 to 15 portions of creat, 10 to 20 portions of herba agrimoniae, 15 to 25 portions of tangerine peel, 10 to 20 portions of aucklandia root, 10 to 20 portions of Chinese bulbul, 15 to 20 portions of Magnolia officinalis, 5 to 15 portions of Chinese gall, 2 to 5 portions of snake gall, 10 to 20 portions of ox-gall, 40 to 60 portions of Chinese aloe, 25 to 40 portions of crystal sugar, 8 to 15 portions of spectinomycin and 10 to 15 portions of lincomycin. The oral liquid synergistic agent can eliminate toxin in blood and toxin invaded from the outside of organisms, has the characteristic of clearing away heat and toxic materials, can treat the colon bacillus and intestinal disease syndrome as proved by a plurality of clinic experimental results, and has high-efficiency treatment effect during the treating process. Moreover, the oral liquid synergistic agent has the advantages of convenience in drinking and administration, high absorptivity, wide distribution, no medicine residue, no toxic side effect, and wide safe range.
Description
[technical field]
The present invention relates to a kind of veterinary's pharmaceutical composition and preparation method thereof.
[background technology]
The colibacillosis of domestic animal, poultry and aquatic animal is a kind of acute infectious disease that is caused by Escherichia coli.Multiple symptoms such as main performance enteritis, enterotoxemia.Primary disease all has generation all over the world, become one of serious hindrance of development aquaculture.
Such as, for domestic animal-pig, colibacillosis is because the trophophase of pig and cause the difference of the colibacillary serotype of morbidity, and the disease that causes thus can be divided into three kinds of yellow scour of piglet, piglet pujos blancos and bowel oedema diseases.Wherein, 1. yellow scour of piglet claims newborn piglet colibacillosis or newborn piglet diarrhoea again, is a kind of acute, the height lethal infectious disease that is infected the newborn piglet that causes by Escherichia coli.7 ages in days are with the easiest infection primary disease of interior piglet, the particularly piglet of 1-3 age in days, and in a brood of piglet, as long as a hair disease is arranged, almost full nest piglet all falls ill in one, two day, and more than 90%, mortality rate is up to 100% usually for sickness rate.2. the piglet pujos blancos piglet pujos blancos be piglet during suckling in common diarrhoeal diseases, sickness rate height and case fatality rate is lower influence the growth in piglets growth.3. the bowel oedema disease bowel oedema disease is a kind of enterotoxemia of young pig after the wean that is caused by Escherichia coli.The fat faster pig of piglet, especially growth promoter that the primary disease pilosity is born in wean back 1-2 week is susceptible disease more, sickness rate about 20%, and case fatality rate is up to 80%.
For another example, chicken colibacillosis is a kind of infectious disease that has the particular serotype escherichia coli to cause.The sick type of this disease is more, and complicated clinical manifestation is various.This disease is the conditionality infectious disease, many secondary or concurrent with other diseases, be most important in the present poultry husbandry also be one of the most thorny infectious disease.Primary disease is to the chicken susceptible, various age chicken all can fall ill, but more with interior chicken morbidity with 4 monthly ages.Primary disease can be through the ovum vertical transmission, and the hatching egg that carries disease germs dead germ may occur in hatching process, and the chickling that hatches mostly is inapparent infection, if can fall ill when running into some factor that reduces resistance.Horizontal transmission can be drunk water by by the feedstuff of e. coli contamination, the pad grass, and Vector of infection such as air, through digestive tract, respiratory tract, approach such as umbilical cord and skin trauma infect.Colibacillosis Chang Xufa or concurrent salmonellosis infectious bronchitis, newcastle, mycoplasma, Bacillus pasteurii disease, bursal disease makes the state of an illness complicated more, and mortality rate increases.Sickness rate can reach more than 50%, and mortality rate reaches about 40%.
For this reason, treat the animal large intestine bacillosis and still will be placed on main energy in the prevention, should prevent that eqpidemic disease from taking place, and also will prevent the diffusion of eqpidemic disease.Aspect prevention animal large intestine bacillosis, improve breeding environment and the various vaccines of inoculation except extremely long-pending, be exactly immunity, the anti-virus ability of conscious raising animal body in breeding process, thereby reduce colibacillary infection probability.
[summary of the invention]
The purpose of this invention is to provide a kind of immunity of organisms, resistance against diseases that can improve domestic animal, poultry and aquatic animal, reduce colibacillary infection probability and improve bacillus coli vaccine oral liquid synergistic agent of bacillus coli vaccine prevention effect and preparation method thereof.
Bacillus coli vaccine oral liquid synergistic agent of the present invention mainly is to be made by the raw material of following weight portion:
Herba Andrographis 5-15 part, Herba Agrimoniae 10-20 part, Pericarpium Citri Reticulatae 15-25 part, Radix Aucklandiae 10-20 part, Radix Pulsatillae 10-20 part, Cortex Magnoliae Officinalis 15-20 part, Galla Chinensis 5-15 part, Fel Serpentis 2-5 part, Fel Bovis seu Bubali 10-20 part, Aloe 40-60 part, crystal sugar 25-40 part, spectinomycin 8-15 part, lincomycin 10-15 part.
Be preferably:
12 parts of Herba Andrographis, 12 parts of Herba Agrimoniaes, 18 parts of Pericarpium Citri Reticulataes, 18 parts of the Radix Aucklandiae, 18 parts of the Radix Pulsatillaes, 16 parts of Cortex Magnoliae Officinalis, 8 parts of Galla Chinensiss, 3 parts of Fel Serpentis, 17 parts of Fel Bovis seu Bubali, 46 parts of Aloes, 30 parts in crystal sugar, 10 parts of spectinomycins, 15 parts of lincomycins.
The preparation method of bacillus coli vaccine oral liquid synergistic agent of the present invention may further comprise the steps:
(1) take by weighing each raw material by described weight ratio, standby;
(2) will decoct with water except that the raw material spectinomycin and the lincomycin twice, each amount of water was not advisable to have former charge level, merge decocting liquid twice, filter to get filtrate, be condensed into proportion and be 1.35 extractum, add 85-95% edible ice acetic acid and carry out lixiviate, reclaim glacial acetic acid and concentrate, dry under 45-50 ℃, make dry extract;
(3) dry extract is broken into powder, adding spectinomycin and lincomycin add 85-95% edible ice acetic acid again after mixing thoroughly, stir evenly to get final product.
The present invention selects the above-mentioned raw materials combination to make each component and effect produce synergism, thereby can improve immunity of organisms, the resistance against diseases of domestic animal, poultry and aquatic animal, reduces colibacillary infection probability and improves the bacillus coli vaccine prevention effect.
Wherein selecting Herba Andrographis for use is because of its heat-clearing and toxic substances removing, removing heat from blood, detumescence.Selecting Herba Agrimoniae for use is because of its astringing to arrest bleeding, preventing the attack (or recurrence) of malaria, dysentery relieving, detoxifcation.Selecting Pericarpium Citri Reticulatae for use is because of its regulating qi-flowing for strengthening spleen, drying dampness to eliminate phlegm.Selecting the Radix Aucklandiae for use is because of its promoting the circulation of QI to relieve pain, strengthening the spleen to promote digestion.Selecting the Radix Pulsatillae for use is because of its heat-clearing and toxic substances removing, eliminating pathogenic heat from blood to cure dysentery.Selecting Cortex Magnoliae Officinalis for use is because of its dampness expectorant, and the therapeutic method to keep the adverse QI flowing downwards is removed full.Select for use Galla Chinensis to be because it is held back pathogenic fire reducing and is, relieving diarrhea with astringents, removing dampness is held back skin ulcer.Select for use Fel Bovis seu Bubali to be because its heat-clearing and toxic substances removing, anemofrigid cold, liver heat removing and eyesight improving, sharp larynx dries, analgesic pathogenic fire purging, toxin expelling, detumescence, promoting the secretion of bile and dredging bowels, clearing away heat and promoting production of body fluid, select for use Aloe to be because its antiviral, antibacterium, heat-clearing and toxin-vanquishing, removing heat from the liver, antibiotic and sterilizing, disease resistance enhancemen, stop virus to invade host cell, suppress the synthetic of its DNA and RNA, suppress the viral growth breeding and play antiviral effect, detoxifcation, human body immunity improving power selects for use crystal sugar to be because its anti-stress, human body immunity improving power, resistance against diseases, blood circulation promoting, and can improve mouthfeel.
Oral liquid synergistic agent of the present invention can purge away the poison in one's blood, and eliminates the outside toxin of invading of organism, has the characteristic of heat-clearing and toxic substances removing, shows through a large amount of clinical experiment results and can treat escherichia coli and the sick comprehensive serious symptom of intestinal.In treatment, played therapeutic effect efficiently.And the drinking-water convenient drug administration, the absorbance height, widely distributed, drug residue free has no side effect, and safety range is wide.
[specific embodiment]
Embodiment one: oral liquid synergistic agent 1 preparation of the present invention
(1) takes by weighing Herba Andrographis 5 grams, Herba Agrimoniae 10 grams, Pericarpium Citri Reticulatae 15 grams, the Radix Aucklandiae 10 grams, the Radix Pulsatillae 10 grams, Cortex Magnoliae Officinalis 15 grams, Galla Chinensis 5 grams, Fel Serpentis 2 grams, Fel Bovis seu Bubali 10 grams, Aloe 40 grams, crystal sugar 25 grams.
(2) raw material is decocted with water twice, for the first time add 8 times of amounts of water, decocted 2 hours, add 6 times of amounts of water for the second time, decocted 1 hour, merge decocting liquid twice, filter to get filtrate, be condensed into proportion and be 1.35 extractum, add 85-95% edible ice acetic acid and carry out lixiviate, reclaim glacial acetic acid and concentrated, dry under 45-50 ℃, make dry extract 14.26 grams;
(3) dry extract is broken into powder, but adds 8 gram spectinomycins, 10 crin mycins, stir;
(4) add 85-95% edible ice acetic acid approximately to 3000ml, stir evenly, get final product.
Embodiment two: oral liquid synergistic agent 2 preparations of the present invention
(1) takes by weighing Herba Andrographis 15 grams, Herba Agrimoniae 20 grams, Pericarpium Citri Reticulatae 25 grams, the Radix Aucklandiae 20 grams, the Radix Pulsatillae 20 grams, Cortex Magnoliae Officinalis 20 grams, Galla Chinensis 15 grams, Fel Serpentis 5 grams, Fel Bovis seu Bubali 20 grams, Aloe 60 grams, crystal sugar 40 grams.
(2) raw material is decocted with water twice, for the first time add 8 times of amounts of water, decocted 2 hours, add 6 times of amounts of water for the second time, decocted 1 hour, merge decocting liquid twice, filter to get filtrate, be condensed into proportion and be 1.35 extractum, add 85-95% edible ice acetic acid and carry out lixiviate, reclaim glacial acetic acid and concentrated, dry under 45-50 ℃, make dry extract 21.4 grams;
(3) dry extract is broken into powder, but adds 10 gram spectinomycins, 15 crin mycins, stir;
(4) add 85-95% edible ice acetic acid approximately to 5000ml, stir evenly, get final product.
Embodiment three: safety of the present invention
1000 ducks are divided into two groups at random, and 1 group of oral liquid synergistic agent of the present invention that adds 100ml in the daily feedstuff of every duck every day adds oral liquid synergistic agent 2 of the present invention for 1,2 group.Observed 30 days.
1000 ducks are all no abnormal in 30 days, are a cup too low depressed or the phenomena of mortality, grow fine.Illustrate that oral liquid synergistic agent security performance of the present invention is good.
Embodiment four: oral liquid synergistic agent of the present invention has preventive effect to the colibacillosis of young pig
Get 40 of young pigs, be divided into four groups at random, 10 every group, normally feed in every day for 1 group, 2 groups every young pig injection normally fed identical swine escherichia coli disease vaccine and every day, 3 groups add 0.5 liter of oral liquid synergistic agent of the present invention and add 0.5 liter of oral liquid synergistic agent 2 of the present invention for 1,4 group.
Raise after 2 days, in four groups, respectively add a pig that suffers from colibacillosis respectively, observe the growing state of respectively organizing young pig.
The results are shown in Table 1.The result shows that oral liquid synergistic agent of the present invention has tangible prevention and therapeutical effect to the colibacillosis of young pig.
Table 1 oral liquid synergistic agent of the present invention is to the preventive and therapeutic effect of the colibacillosis of young pig
Embodiment five: oral liquid synergistic agent of the present invention has prevention and promotes the growth effect the colibacillosis of chicken
Get 400 of young chickens, be divided into four groups at random, every group 100, normally feed in every day for 1 group, 2 groups add 0.5 liter of (concentration 1%) oxytetracycline solution, 3 groups add 0.5 liter of (about concentration 1%) oral liquid synergistic agent of the present invention and add 0.5 liter of (about concentration 1%) oral liquid synergistic agent 2 of the present invention for 1,4 group.
After raising for 1 week, after each group only adds 2 chickens that suffer from colibacillosis, raised for 3 weeks again, observe the growing state of respectively organizing chicken.
The results are shown in Table 2.The result shows that oral liquid synergistic agent of the present invention has tangible prevention and promotes the growth effect the colibacillosis of chicken.
Table 2 oral liquid synergistic agent of the present invention is to the control and the promotion growth effect of the colibacillosis of chicken
Annotate: increase the preceding average weight (g) of average weight (g)/experiment after ratio=January
Claims (3)
1. bacillus coli vaccine oral liquid synergistic agent that is used for domestic animal, poultry and aquatic animal, it is characterized in that: it is to be made by the following medicaments in part by weight raw material:
Herba Andrographis 5-15 part, Herba Agrimoniae 10-20 part, Pericarpium Citri Reticulatae 15-25 part, Radix Aucklandiae 10-20 part, Radix Pulsatillae 10-20 part, Cortex Magnoliae Officinalis 15-20 part, Galla Chinensis 5-15 part, Fel Serpentis 2-5 part, Fel Bovis seu Bubali 10-20 part, Aloe 40-60 part, crystal sugar 25-40 part, spectinomycin 8-15 part, lincomycin 10-15 part.
2. oral liquid synergistic agent as claimed in claim 1 is characterized in that: it is to be made by the following medicaments in part by weight raw material:
12 parts of Herba Andrographis, 12 parts of Herba Agrimoniaes, 18 parts of Pericarpium Citri Reticulataes, 18 parts of the Radix Aucklandiae, 18 parts of the Radix Pulsatillaes, 16 parts of Cortex Magnoliae Officinalis, 8 parts of Galla Chinensiss, 3 parts of Fel Serpentis, 17 parts of Fel Bovis seu Bubali, 46 parts of Aloes, 30 parts in crystal sugar, 10 parts of spectinomycins, 15 parts of lincomycins.
3. the preparation method of oral liquid synergistic agent as claimed in claim 1 or 2 may further comprise the steps:
(1) take by weighing each raw material by described weight ratio, standby;
(2) will decoct with water except that the raw material spectinomycin and the lincomycin twice, each amount of water was not advisable to have former charge level, merge decocting liquid twice, filter to get filtrate, be condensed into proportion and be 1.35 extractum, add 85-95% edible ice acetic acid and carry out lixiviate, reclaim glacial acetic acid and concentrate, dry under 45-50 ℃, make dry extract;
(3) dry extract is broken into powder, adding spectinomycin and lincomycin add 85-95% edible ice acetic acid again after mixing thoroughly, stir evenly to get final product.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100290615A CN101313978B (en) | 2008-06-27 | 2008-06-27 | Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2008100290615A CN101313978B (en) | 2008-06-27 | 2008-06-27 | Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101313978A CN101313978A (en) | 2008-12-03 |
| CN101313978B true CN101313978B (en) | 2010-12-15 |
Family
ID=40105222
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2008100290615A Expired - Fee Related CN101313978B (en) | 2008-06-27 | 2008-06-27 | Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101313978B (en) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN106177221B (en) * | 2016-08-18 | 2020-06-05 | 中国农业科学院兰州畜牧与兽药研究所 | Traditional Chinese medicine composition for treating porcine colibacillosis diarrhea and preparation method thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1380098A (en) * | 2002-05-20 | 2002-11-20 | 张勇飞 | Anti-infection compound preparation and its preparation method |
| CN1559470A (en) * | 2004-03-01 | 2005-01-05 | 王原成 | Chinese patent drug for livestock |
| CN101152317A (en) * | 2007-09-24 | 2008-04-02 | 周家华 | Traditional Chinese medicine for treating self-dysentery and diarrhea of birds |
-
2008
- 2008-06-27 CN CN2008100290615A patent/CN101313978B/en not_active Expired - Fee Related
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1380098A (en) * | 2002-05-20 | 2002-11-20 | 张勇飞 | Anti-infection compound preparation and its preparation method |
| CN1559470A (en) * | 2004-03-01 | 2005-01-05 | 王原成 | Chinese patent drug for livestock |
| CN101152317A (en) * | 2007-09-24 | 2008-04-02 | 周家华 | Traditional Chinese medicine for treating self-dysentery and diarrhea of birds |
Also Published As
| Publication number | Publication date |
|---|---|
| CN101313978A (en) | 2008-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN103006792B (en) | A kind of herbal medicine for preventing and treating livestock and poultry intestinal canal diseases and preparation method thereof and feed | |
| CN102772478B (en) | Traditional Chinese medicine granule for enhancing immunity of livestock and poultry | |
| CN103230574B (en) | Traditional Chinese medical composition for treating porcine epizootic diarrhea and application thereof | |
| CN102028795B (en) | Chinese pulsatilla root granules for preventing and treating livestock and poultry bacterial diseases and preparation method and premix thereof | |
| CN103394053A (en) | Traditional Chinese medicine composition capable of preventing and treating piglet yellow and white scours as well as preparation and applications thereof | |
| CN101209307A (en) | Chinese medicinal oral liquid with heat-clearing and detoxication, dampness-eliminating and dysentery-stopping efficacy | |
| CN102671011B (en) | Traditional Chinese medicine compound powder for preventing and treating yellow and white scour of piglets and preparation method thereof | |
| CN101396462A (en) | Traditional Chinese medicine oral liquid for treating livestock and poultry digestive canal disease | |
| CN101259160A (en) | Compound preparations for treating birdsvirosis and preparation thereof | |
| CN101313978B (en) | Bacillus coli vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof | |
| CN101595945A (en) | A kind of feed addictive that promotes production, strengthens the animal disease resistant ability | |
| CN101390965A (en) | Veterinary traditional Chinese herb medicine for treating livestock and poultry bacterial and viral infectious diseases and preparation method thereof | |
| CN104147467B (en) | Traditional Chinese medicine for treating endotoxemia of poultry and livestock and preparation process thereof | |
| CN102885927A (en) | Traditional Chinese medicine composition for treating pullorum disease and preparation method thereof | |
| CN106727824A (en) | The preparation method and application of chrysanthemum leaf Notogineng Extract and its compound preparation | |
| CN101376006A (en) | Chinese medicine oral liquid with heat-clearing and detoxicating, cough-suppressing and asthma-relieving functions as well as application thereof for livestock and poultry | |
| CN107789394B (en) | Composition for treating livestock and poultry diarrhea | |
| CN104606627B (en) | A kind of pharmaceutical composition for treating grice diarrhoea and preparation method thereof | |
| CN102091321A (en) | Medicament oral liquid for treating enteritis and diarrhea and preparation method thereof | |
| CN101313977B (en) | Intestine toxicity syndrome vaccine oral liquid synergistic agent for livestock, poultry and aquatic product, and preparation method thereof | |
| CN110652543A (en) | Preparation method and application of Chinese herbal medicine preparation for treating live pig viral enteritis | |
| CN105053655B (en) | It is a kind of that a kind feed for duck brood time survival rate can be improved | |
| CN101396453A (en) | Traditional Chinese medicine oral liquid for treating livestock and poultry respiratory passage and digestive canal infection | |
| CN101279028A (en) | Oral liquid vaccine for preventing and controlling avian influenza of domestic animals and domestic birds and method of preparing the same | |
| CN106692711A (en) | Traditional Chinese medicine drug granule of nestling initial drug and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C41 | Transfer of patent application or patent right or utility model | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20090109 Address after: Liwan District City, Guangdong Province, Guangzhou Fengyuan Road No. 130 post encoding: 510070 Applicant after: Lei Qing Lian Co-applicant after: He Hong Address before: Liwan District City, Guangdong Province, Guangzhou Fengyuan Road No. 130 post encoding: 510070 Applicant before: Lei Qinglian |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| ASS | Succession or assignment of patent right |
Owner name: ZHUHAI KANGYIDA BIO-TECHNIQUE CO., LTD. Free format text: FORMER OWNER: LEI QINGLIAN Effective date: 20120121 Free format text: FORMER OWNER: HE JIANG Effective date: 20120121 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 510070 GUANGZHOU, GUANGDONG PROVINCE TO: 519040 ZHUHAI, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120121 Address after: 519040 Guangdong city of Zhuhai province Jinwan District Jin Haian Avenue (Jin Haian Biotechnology Park No. 15) Patentee after: Zhuhai Kangyida Bio-Technique Co., Ltd. Address before: Liwan District City, Guangdong Province, Guangzhou Fengyuan road 510070 No. 130 Co-patentee before: He Hong Patentee before: Lei Qinglian |
|
| ASS | Succession or assignment of patent right |
Owner name: ZHANJIANG TAIYUAN BIO-TECHNOLOGY ENGINEERING CO., Free format text: FORMER OWNER: ZHUHAI KANGYIDA BIO-TECHNIQUE CO., LTD. Effective date: 20120423 |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| COR | Change of bibliographic data |
Free format text: CORRECT: ADDRESS; FROM: 519040 ZHUHAI, GUANGDONG PROVINCE TO: 519040 ZHANJIANG, GUANGDONG PROVINCE |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20120423 Address after: The 519040 Zhanjiang Xiashan China Industrial Zone Huagang Road No. six Patentee after: Zhanjiang Taiyuan Biological Engineering Co., Ltd. Address before: 519040 Guangdong city of Zhuhai province Jinwan District Jin Haian Avenue (Jin Haian Biotechnology Park No. 15) Patentee before: Zhuhai Kangyida Bio-Technique Co., Ltd. |
|
| C41 | Transfer of patent application or patent right or utility model | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20160322 Address after: The Town Tower Ridge Development Zone 571299 Hainan province Dingan County Patentee after: An aerobic biological engineering Co. Ltd. Address before: Huagang road Zhanjiang Xiashan China Industrial Zone No. six Patentee before: Zhanjiang Taiyuan Biological Engineering Co., Ltd. |
|
| TR01 | Transfer of patent right |
Effective date of registration: 20170601 Address after: 110117, No. 42-8, Rong Rong Road, Heping District, Liaoning, Shenyang Patentee after: Shenyang Tian Peng animal health care products factory Address before: The Town Tower Ridge Development Zone 571299 Hainan province Dingan County Patentee before: An aerobic biological engineering Co. Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20170830 Address after: 110000, No. 42-8, Rong Rong Road, Heping District, Liaoning, Shenyang Patentee after: Liaoning days of Biotechnology Co., Ltd. Peng Address before: No. 42-8, Rong Rong Road, Heping District, Shenyang Patentee before: Shenyang Tian Peng animal health care products factory |
|
| TR01 | Transfer of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20101215 Termination date: 20180627 |
|
| CF01 | Termination of patent right due to non-payment of annual fee |